Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Thursday, February 26, 2015 at 4:30 p.m. ET

NOVATO, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release fourth quarter and full year 2014 financial results on Thursday, February 26, 2015 after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the financial results and provide a corporate update.

Dial-in Information
U.S. Dial-in Number: (888) 346-9290
International Dial-in Number: (412) 902-4275
Conference ID: 10060686
Replay U.S. Dial-in Number: (877) 344-7529
Replay International Dial-in Number: (412) 317-0088
Conference ID: 10060686

An audio webcast will be available online in the investor relations section of the company website at www.raptorpharma.com, with a webcast replay accessible after the call.

About Raptor Pharmaceutical

Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic steatohepatitis (NASH), and Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. A request for EU orphan designation for RP103 in HD has been submitted. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit www.raptorpharma.com.


Contact Data